Our integrated sterile production lines deliver turnkey, fully automated manufacturing solutions purpose-built for parenteral drug production, covering liquid injections, lyophilized formulations, vialed medications, and other sterile injectable products. Engineered to meet the most stringent cGMP, FDA and EMA regulatory criteria, the system unifies upstream liquid preparation, inline sterile processing, precision filling, sealing, and post-production handling into a seamless closed manufacturing workflow, ensuring superior sterility assurance and batch consistency for high-grade parenteral pharmaceuticals.
Featuring a highly integrated modular architecture, the production line minimizes manual intervention and eliminates cross-contamination risks throughout the entire manufacturing process. It integrates core functional units including water for injection (WFI) preparation, sterile liquid batching, laminar flow protection, high-precision dosing, automated stoppering and capping, as well as inline visual inspection. The unified mechanical and control system ensures process synergy, stable operation rhythm, and outstanding production efficiency for diverse parenteral product portfolios.
Equipped with full-process sterile guarantee mechanisms, the line supports automated CIP/SIP cycles, classified clean zone environmental control, and real-time monitoring of critical process parameters such as temperature, pressure, humidity and particle count. All operational data is digitally recorded and traceable, supporting complete process validation, regulatory inspection and quality compliance for commercial parenteral production.
Designed for industrial scalability and operational flexibility, our integrated sterile lines accommodate flexible production specifications, enabling rapid switching between different container types and dosage volumes. With high operational stability, low failure rate and intelligent process management, the solution helps pharmaceutical manufacturers reduce production costs, shorten validation cycles, and build reliable, high-yield sterile parenteral manufacturing capabilities for long-term commercial operation.
